Scarica l'app Stockscreener
47.01
4.13%
-2.09
Uniqure Nv Borsa (QURE) Ultime notizie
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD FilingHas The Bull Case Changed? - simplywall.st
uniQure prices upsized $225M public offering of ordinary shares - MSN
Price to sales forward of uniQure N.V. – LSX:A1XDTV - TradingView
uniQure closes $259M public offering at $45.50 per share By Investing.com - Investing.com South Africa
uniQure Closes $259 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Closing of Upsized Public Offering and - GlobeNewswire
Kapusta (QURE) sells 28,716 shares after option exercise on 06/25/2026 - Stock Titan
Price to earnings forward of uniQure N.V. – LSX:A1XDTV - TradingView
Price to book forward of uniQure N.V. – LSX:A1XDTV - TradingView
Enterprise value to EBIT forward of uniQure N.V. – LSX:A1XDTV - TradingView
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight - PR Newswire UK
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances - Yahoo Finance
Mizuho raises uniQure stock price target to $68 on FDA meeting optimism - Investing.com
uniQure Prices Upsized $225 Million Public Offering to Advance Gene Therapy Pipeline - Minichart
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $68 - Moomoo
uniQure Prices $45.50 Stock Offering; Underwriting With Leerink Partners Nets $242.7 Million - TradingView
uniQure (NASDAQ: QURE) prices $225M underwritten share offering - Stock Titan
uniQure (NASDAQ: QURE) raises $211.5M net to fund AMT-130 launch plans - Stock Titan
uniQure (NASDAQ: QURE) files Rule 144 resale notice listing recent insider sales - Stock Titan
UniQure (QURE) Gains Regulatory Support from FDA Under New Leade - GuruFocus
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
uniQure N.V. (QURE) Prices $225M Public Offering of Shares - GuruFocus
What’s next in line for FDA reversals (RGNX:NASDAQ) - Seeking Alpha
uniQure N.V. (QURE) Stock Dips Following $225M Share Offering Announcement - Blockonomi
UniQure Prices $225 Million Ordinary Stock Offering - Moomoo
uniQure prices $225M public offering at $45.50 per share By Investing.com - Investing.com Australia
QURE Raises Offering Size to $225M, Priced Below Previous Close - GuruFocus
uniQure (QURE) Shares Climb 7.6% with Notable Price Increase - GuruFocus
uniQure locks in $225M from a new share sale - Stock Titan
uniQure prices $225M public offering at $45.50 per share - Investing.com
UniQure Announces Pricing of $225 Million Public Offering of Ordinary Shares - Moomoo
uniQure Announces Pricing of $225 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Pricing of Upsized $225 Million Public Offering - GlobeNewswire
Gene Therapy AMT-260 Shows Early Seizure Reductions in Refractory Mesial Temporal Lobe Epilepsy, Phase 1 Cohort Data Show - NeurologyLive
QURE Stock Soars As FDA Backs Accelerated Huntington’s Therapy Path - timothysykes.com
Barclays Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
QURE Stock Roars As FDA Clears Faster Path For AMT-130 - StocksToTrade
uniQure initiates $150 million public offering - The Pharma Letter
symbol__ Stock Quote Price and Forecast - CNN
uniQure commences $150 million public offering of shares - Investing.com UK
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
uniQure (QURE) Launches $150M Public Offering Amid After-Hours D - GuruFocus
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE: New Offering Managed by Leerink Partners and Stifel - GuruFocus
UniQure's experimental drug shows early promise in difficult-to-treat epilepsy - MSN
uniQure (NASDAQ: QURE) seeks $150M in equity and pre-funded warrants ahead of AMT-130 BLA - Stock Titan
uniQure commences $150 million public offering of shares By Investing.com - Investing.com South Africa
UniQure Announces Planned $150 Million Public Offering - marketscreener.com
0.90%
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):